

ongoing trials - trial from other registries

Maralixibat in Patients With Cystic Fibrosis and Constipation, A Within-Subjects Pilot Study - - NOT_YET_RECRUITING

Code: NCT06413368 **Year:** 2024 **Date:** new

Author:

Participants

15 patients 0-17 years with Cystic Fibrosis

Interventions

VX-121/VX-661/VX-561 Film-coated tablet, Kalydeco 75 mg film-coated tablets, VX-445/VX-661/VX-770 film-coated fixed-dose combination tablet, VX-121/VX-661/VX-561 Film-coated tablet, Kaftrio 37.5 mg/25 mg/50 mg film-coated tablets, Kalydeco 150 mg film-coated tablets, VX-445/VX-661/VX-770 fixed-dose combination tablet

Outcome measures

Part A: PK parameters of VX-121, TEZ, D-IVA, and relevant metabolites, Part A: Safety and tolerability as determined by adverse events (AEs), clinical laboratory values, standard 12 lead ECGs, vital signs, and pulse oximetry, Part B: Safety and tolerability as determined by AEs, clinical laboratory values, standard 12-lead ECGs, vital signs, and pulse oximetry

<https://clinicaltrials.gov/study/NCT06413368>

Keywords

CFTR Modulators; Genetic Predisposition to Disease; pharmacological_intervention; placebo; VX-770; VX-121; ivacaftor; Aminophenols; tezacaftor; VX-661; vanzacaftor; deutivacaftor; elexacaftor; VX-445; VX-561;